This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ENSG's Q2 Earnings Beat on Higher Occupancy Rates, Stock Up 9%
by Zacks Equity Research
Ensign Group's Q2 earnings improve 20.5% year over year, fueled by stronger occupancy, patient days and rental revenues.
HCA Beats Q2 Earnings on Higher Admissions, Ups '25 EPS View
by Zacks Equity Research
HCA Healthcare's Q2 earnings rose 24% year over year on stronger patient volumes. EPS for 2025 is expected to be within $25.5-$27, up from the earlier view of $24.05-$25.85.
EW Stock Climbs on Q2 Earnings & Revenue Beat, Margins Down
by Zacks Equity Research
Edwards Lifesciences posts a second-quarter 2025 earnings and revenue beat, with strong growth in TAVR and TMTT segments despite margin pressure.
Compared to Estimates, Edwards Lifesciences (EW) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings
by Zacks Equity Research
EW's Q2 earnings report is likely to benefit from soaring TMTT sales, with the segment expected to jump over 57% year over year.
Curious about Edwards Lifesciences (EW) Q2 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Should You Add Edwards Lifesciences Stock to Your Portfolio Now?
by Zacks Equity Research
EW gains traction with surgical tech and TAVR growth, but macro pressures and FX headwinds weigh on margins.
Smart Money Going in Senior Health: Key Stocks in Elderly Care
by Urmimala Biswas
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
BSX Raises 2025 Financial Outlook: What's Backing It?
by Sridatri Sarkar
Boston Scientific lifts its 2025 sales and EPS outlook after a strong Q1, with cardiology and EP segments fueling major gains.
ISRG's Minimally Invasive Ecosystem Powers Surgical Precision
by Indrajit Bandyopadhyay
ISRG's robotic platforms, led by da Vinci and Ion, are transforming surgical precision and driving strong stock gains.
Why Is Accuray (ARAY) Up 17% Since Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock
by Zacks Equity Research
EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
by Zacks Equity Research
EW stock is on investors' radars due to the promising structural heart opportunities and impressive TMTT portfolio.
Top Research Reports for Verizon Communications, Bristol-Myers Squibb & Canadian Pacific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications Inc. (VZ), Bristol-Myers Squibb Co. (BMY) and Canadian Pacific Kansas City Ltd. (CP), as well a micro-cap stock Nova LifeStyle, Inc. (NVFY).
EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised
by Zacks Equity Research
Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat patients with structural heart disease.
Edwards Lifesciences (EW) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Edwards Lifesciences (EW) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings
by Zacks Equity Research
EW's first-quarter 2025 performance is likely to have gained from growth drivers across its businesses amid macroeconomic headwinds.
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
by Zacks Equity Research
EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.
EW Stock Up on Q4 Earnings and Revenue Beat, Margins Crash
by Zacks Equity Research
Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart ??? in the fourth quarter of 2024.
Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Mettler-Toledo (MTD) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Mettler-Toledo (MTD) delivered earnings and revenue surprises of 6.16% and 3.51%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
DexCom (DXCM) Q4 Earnings Preview: What's in the Cards?
by Zacks Equity Research
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insights Into Edwards Lifesciences (EW) Q4: Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
ITGR or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?